연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1780 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Ueno, M. | Ueno, M | 2 | Kanagawa Canc Ctr, Gasteroenterol Dept, Yokohama, Kanagawa, Japan | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Yoo, C. | Yoo, C | 3 | Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Ren, Z. | Ren, Z | 4 | Fudan Univ, Dept Hepat Oncol, Zhongshan Hosp, Shanghai, Peoples R China | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Furuse, J. | Furuse, J | 5 | Kanagawa Canc Ctr, Dept Gastroentel, Yokohama, Tokyo, Japan | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Kelley, R. K. | Kelley, RK | 6 | UCSF Univ Calif San Francisco Parnassus Campus, Med Hematol Oncol, San Francisco, CA USA | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Chan, S. L. | Chan, SL | 7 | Chinese Univ Hong Kong Sino Bldg, Dept Clin Oncol, Hong Kong, Peoples R China | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Edeline, J. | Edeline, J | 8 | Ctr Eugene Marquis, Dept Med Oncol, Rennes, France | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Klumpen, H. J. | Klumpen, HJ | 9 | Vrije Univ, Med Oncol Dept ment, Amsterdam UMC, Med Ctr VUmc, Amsterdam, Netherlands | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Yau, T. | Yau, T | 10 | Univ Hong Kong, Med Dept, Queen Mary Hosp, Pokfulam, Hong Kong, Peoples R China | B-3429-2011 | Yau, Thomas | ||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Oh, S. C. | Oh, SC | 11 | Korea Univ, Oncol, Seoul, South Korea | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Ozaka, M. | Ozaka, M | 12 | Canc Inst Hosp JFCR, Dept Gastroenterol, Koto Ku, Tokyo, Japan | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Kim, J. G. | Kim, JG | 13 | Kyungpook Natl Univ, Oncol Dept, Chilgok Hosp, Daegu, South Korea | ||||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Park, J. O. | Park, JO | 14 | Sungkyunkwan Univ, Samsung Med Ctr SMC, Sch Med, Oncol, Seoul, South Korea | IQU-2241-2023 | Park, Junsu | ||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Vogel, A. | Vogel, A | 15 | MHH Med Hsch Hannover, Gastro Hepato & Endocrinol Dept, Hannover, Germany | A-8437-2012 | Vogel, Arndt | ||||
| Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | Valle, J. W. | Valle, JW | 16 | Christie NHS Fdn Trust, Med Oncol Dept, Manchester, Lancs, England | J-3571-2015 | Valle, Juan |
페이지 이동: